Efficacy Study of Homeopathic Medicines in Treatment of Allergic Rhinitis and/or Induced Bronchial Asthma

An Evidence-based Single-blind Randomized Controlled Trial Searching for the Efficacy of Homoeopathic Medicines in Reducing Serum Levels of Cytokines (IL - 10, 13) and Immunoglobulin E in Allergic Rhinitis and/or Induced Bronchial Asthma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02255136

Acronym

SBRCTHILARBA

Enrollment

100

Registered

2014-10-02

Start date

2012-03-31

Completion date

2018-04-30

Last updated

2018-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinitis; Allergic, With Asthma

Keywords

Interleukin, Immunoglobulin, Homeopathy, Allergic Rhinitis, Asthma

Brief summary

The purpose of this study is to test whether individualized homeopathic medicines can produce any significant effect beyond placebo in treatment of allergic rhinitis and/or induced bronchial asthma

Detailed description

A prospective, single-blind (subject), randomized, placebo-controlled, parallel group, interventional clinical trial is being conducted on 100 participants (subjects 50, control 50) suffering from allergic rhinitis and/or induced bronchial asthma since March 1, 2012 at Mahesh Bhattacharyya Homeopathic Medical College and Hospital, Government of West Bengal. This trial is aimed at exploring the efficacy of homeopathic medicines in comparison with placebo in reducing serum interleukin 10, 13 and immunoglobulin E measured at timeline of 1 year of treatment and absolute eosinophil count every 4 months up to 1 year. Matching for independent and consequent variables will be done to test for bias. Parametric or non-parametric tests will be employed as per distribution of data at the end of the trial.

Interventions

OTHERIndividualized homeopathic medicines

5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year

OTHERPlacebo

Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Intervention model description

Prospective, single-blind (subject), randomized, placebo-controlled, parallel group, interventional clinical trial

Eligibility

Sex/Gender

ALL

Age

5 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age between 5 and 65 years * Both sexes * Atopic: reactive to allergens with positive skin prick test (SPT) results and/or eosinophilia * More than 1 year history of allergic rhinitis and/or induced bronchial asthma

Exclusion criteria

* Nasal abnormalities causing obstruction, e.g. nasal polyp(s), deviated septum etc. * Previous homoeopathic immunotherapy for allergic rhinitis * Allergen avoidance in past 6 weeks * Away from usual environment for more than 1 week during trial * Severe asthma cases as detected clinically * Respiratory infection * Severe concomitant disease * Pregnancy, breast feeding, or likelihood of pregnancy * Oral or parenteral steroids and/or decongestant in past 6 months * Conventional desensitization in past 3 months

Design outcomes

Primary

Measure	Time frame
Serum Interleukin 10 and 13 level	1 year

Secondary

Measure	Time frame
Incidence of adverse events if any	1 year

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026